Namir Hassan
Company: Zelluna Immunotherapy
Job title: Chief Executive Officer
Seminars:
TCR-NK: A Novel Paradigm to Drive Durable Responses in Solid Cancers 3:15 pm
TCR based therapies have shown compelling tumour responses across various solid cancers; however, virtually all patients with advanced solid tumours showing initial response to treatment relapse Heterogeneity of target expression and / or loss of target have been clinically demonstrated to drive relapse in patients where cancers evade T cell recognition Arming NK cells with…Read more
day: Day 1 - Track A - Mid